GLP-1s and Gastroparesis: Weighing the Risk

GLP-1 receptor agonists work, in part, by slowing how quickly the stomach empties into the small intestine. That delay blunts the post-meal glucose spike and stretches out fullness. It is also, almost by definition, a mild and intentional form of delayed gastric emptying. So when reports surfaced of more severe stomach problems in some users, the question became less “could this happen?” and more “how often, and for whom?”

What’s mechanism and what’s a problem

For most people, slowed gastric emptying is the desired effect and never crosses into pathology. The concern is the tail of the distribution: a smaller group who develop persistent nausea, vomiting, early satiety, or, rarely, a clinical diagnosis of gastroparesis.

The most cited real-world estimate comes from a 2023 JAMA research letter by Sodhi and colleagues, which used a database of about 16 million patients to compare new GLP-1 users (taking the drugs for weight loss) against users of bupropion-naltrexone.

Relative to bupropion-naltrexone, GLP-1 use was associated with a higher risk of gastroparesis (hazard ratio 3.7; 95% CI 1.2–11.9) and bowel obstruction (HR 4.2; 95% CI 1.0–17.4). The relative risk is elevated, but these events were uncommon in absolute terms, and the wide confidence intervals reflect how few cases occurred.

So the signal is real but small in absolute frequency. People with pre-existing motility disorders or diabetic gastroparesis plausibly start at higher baseline risk.

Practical signs worth attention

• Nausea or vomiting that does not settle after the first few weeks
• Feeling full after only a few bites, persistently
• Vomiting undigested food eaten hours earlier

These warrant a conversation with the prescriber rather than waiting them out.

A real anesthesia consideration

The most concrete, well-documented issue is retained stomach contents during procedures requiring sedation. Because emptying is slowed, food can remain in the stomach longer than expected, raising aspiration risk. In 2023 the American Society of Anesthesiologists issued consensus guidance recommending that weekly-dosed GLP-1 agonists be held for about a week before procedures requiring sedation — guidance the society itself flagged as based on limited data. Later multisociety guidance moved toward a more individualized approach (assessing residual gastric contents, sometimes with ultrasound), but the underlying concern is genuine and actionable.

The takeaway

Slowed gastric emptying is the point of these drugs, and for most users it stays in the territory of a tolerable side effect that fades. Severe gastroparesis and bowel obstruction appear uncommon, though the relative risk is measurably higher than a comparator, and the data lean on claims-based estimates with wide uncertainty. The clearest action item is procedural: tell your anesthesia team you are on a GLP-1. Beyond that, persistent gut symptoms deserve evaluation rather than endurance.

Sources

• Sodhi et al., Risk of Gastrointestinal Adverse Events with GLP-1 Agonists for Weight Loss, JAMA 2023 (PubMed)
• GI Adverse Events with GLP-1 Agonists for Weight Loss (American College of Gastroenterology, EBGI)